Targeted neuromodulation may be a future method to help those with severe, untreatable depression - traditionally, this is used to correct misfiring brain circuits in people with epilepsy or Parkinson's.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.
Aarthi JanakiRaman, Research Director, Chemicals and Advanced Materials at TechVision, Frost & Sullivan, explains how glycoscience offers opportunities galore in healthcare.
In Bangladesh, children are fighting a difficult battle to survive antibiotic resistance - now, mid-pandemic, pneumonia is becoming untreatable via normal drugs.
